LEXXLexaria Bioscience Corp.
10.91USDMkt Cap: 18.04M $P/E: —3d ago
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap18.04M $
Enterprise Value15.10M $
Revenue (TTM)194.00K $
Gross Profit703.20K $
Net Income (TTM)-11.90M $
Revenue/Share0.1290 USD
Last Price10.91 USD
Fiscal Year EndAug 2025
MR QuarterMay 2026
Employees7
CountryUS
SectorConsumer Defensive
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-28.90
PEG—
EV/EBITDA-2.04
EV/Revenue77.81
P/S96.00
P/B3.93
EPS (TTM)-5.04
EPS (Forward)-0.39
52W Range
10.8016% of range11.53
52W High11.53 USD
52W Low10.80 USD
Profitability
Gross Margin99.61%
Oper. Margin-3862.94%
EBITDA Margin0.00%
Profit Margin-1686.00%
ROE-398.10%
ROA-285.07%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.45M $
CapEx (TTM)99.75K $
FCF Margin-2416.61%
FCF Yield-25.99%
Net Debt-3.53M $
Net Debt/EBITDA0.48
Balance Sheet
Debt/Equity0.04
Current Ratio10.60
Quick Ratio9.56
Book Value/Sh2.867 USD
Cash/Share2.189 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 12, 2021
Splits
Last Split1:15
Split DateAug 3, 2026
Analyst Consensus
Rating—
Target (Mean)52.50 USD
Upside (mean)+381.0%
Target Range22.50 USD – 82.50 USD
$22.50+381.0% to mean$82.50
# Analysts2
Ownership
Shares Out.1.65M
Float1.60M
Insiders3.32%
Institutions6.62%
Short Interest
Short Ratio2.0d
Short % Float1.02%
Short % Out.0.98%
Shares Short16.27K
Short (prev mo.)22.87K
Technical
SMA 508.222 (+32.7%)
SMA 20011.13 (-1.9%)
Beta0.37
S&P 52W Chg21.00%
Avg Vol (30d)8.59K
Avg Vol (10d)37.73K
Technical Indicators
RSI (14)66.7
MACD0.8008
MACD Signal0.1350
MACD Hist.+0.6658
BB Upper12.37 USD
BB Middle7.620 USD
BB Lower2.869 USD
BB Width124.70%
ATR (14)1.063 USD
Vol Ratio (20d)0.23x